2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Apolipoprotein
  5. Apolipoprotein Isoform

Apolipoprotein

 

Apolipoprotein Related Products (16):

Cat. No. Product Name Effect Purity
  • HY-P1050A
    COG 133 TFA
    		99.58%
    COG 133 TFA is a fragment of Apolipoprotein E (APOE) peptide. COG 133 TFA competes with the ApoE holoprotein for binding the LDL receptor, with potent anti-inflammatory and neuroprotective effects. COG 133 TFA is also a nAChR antagonist with an IC50 of 445 nM.
  • HY-132820
    Inaxaplin
    		Inhibitor 99.44%
    Inaxaplin (VX-147) is an orally active apolipoprotein L1 (APOL1) function inhibitor (WO2020131807, compound 2). Inaxaplin can be used for the research of kidney disease.
  • HY-147425A
    Zerlasiran sodium
    		Inhibitor
    Zerlasiran sodium is an apolipoprotein A (ApoA) synthesis reducer.
  • HY-P99105
    Anselamimab
    		98.96%
    Anselamimab (CAEL-101) a humanized IgG1-κ anti-Amyloid fibrils antibody targeting to serum amyloid A1 (SAA1).
  • HY-P6306
    CS-6253
    		Agonist
    CS-6253 is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles.
  • HY-P6365A
    APL180
    APL180 (L-4F) is an apolipoprotein A-I mimic peptide, that improves the anti-inflammatory activity of high-density lipoprotein (HDL). APL180 can be used in researches of cardiovascular diseases.
  • HY-169932
    APOL1-IN-2
    		Inhibitor
    APOL1-IN-2 (Compound 467) is the inhibitor for Apolipoprotein 1 (APOL1). APOL1-IN-2 reduces the APOL1 G2/G1 induced cell death in HEK293 with EC50 of 4.74 nM and 14.3 nM. APOL1-IN-2 reduces the APOL1 G2/G1/G0 induced death of trypanosomes with EC50 of 2.24, 6.03 and 3.72 nM, respectively.
  • HY-141885
    APOL1-IN-1
    		Inhibitor 99.85%
    APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD).
  • HY-143200
    OSBPL7-IN-1
    		Inhibitor 99.79%
    OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.
  • HY-151123A
    Pelacarsen sodium
    Pelacarsen sodium is a liver-specific antisense oligonucleotide against apolipoprotein(a) that reduces lipoprotein(a) up to 80% with good tolerability.
  • HY-151123
    Pelacarsen
    Pelacarsen (AKCEA-APO(a)-LRx) is a liver-specific antisense oligonucleotide against apolipoprotein(a) that reduces lipoprotein(a) up to 80% with good tolerability.
  • HY-147425
    Zerlasiran
    		Inhibitor
    Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer.
  • HY-169080
    ABCA1 inducer 1
    		Inducer
    ABCA1 inducer 1 is a nonlipogenic ABCA1 inducer. ABCA1 inducer 1 increases ABCA1 expression, enhances apolipoprotein (APOE) lipidation and reverses multiple Alzheimer’s disease (AD) phenotypes, without increasing triglycerides in E3/4FAD mice that express human APOE 3/4.
  • HY-165061
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
    		Inhibitor
    5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
  • HY-P6365B
    APP-018
    APP-018 (D-4F) is 18 D-amino acids peptide that mimics apolipoprotein A-I (apoA-I). APP-018 improves the anti-inflammatory activity of high-density lipoprotein (HDL). APP-018 can be used in researches of cardiovascular diseases.
  • HY-P6306A
    CS-6253 TFA
    		Agonist
    CS-6253 TFA is the TFA salt form of CS-6253 (HY-P6306). CS-6253 TFA is an agonist for ATP-binding cassette 1 (ABCA 1). CS-6253 TFA improves the amyloid-β42/40 ratio, and affects lipoprotein metabolism in plasma. CS-6253 TFA generates cholesterol-rich high-density lipoprotein (HDL) particles, and induces the release of microparticles.